---
figid: PMC10300409__gr2
pmcid: PMC10300409
image_filename: gr2.jpg
figure_link: /pmc/articles/PMC10300409/figure/fig2/
number: Figure 2
figure_title: ''
caption: Cytotoxicity and replication characteristics of the developed strains(A)
  Viability of BHK-21, 4T1, and CT26 cells through 120 h after infection (h.p.i) by
  MOI 1 of LIVP-RFP, LIVP-IL15-RFP, LIVP-IL15Rα-RFP, and combination of LIVP-IL15-RFP
  with LIVP-IL15Rα-RFP (LIVP-IL15-RFP + LIVP-IL15Rα-RFP). (B) Kinetics of recombinant
  viral strains in different cell lines (BHK-21,4T1, CT26). ANOVA was performed for
  statistical analysis, ∗p < 0.05 and ∗∗p < 0.01 indicate significance.
article_title: Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15
  pathway elicits a synergistic response.
citation: Yasmin Shakiba, et al. Mol Ther Oncolytics. 2023 Jun 15;29:158-168.
year: '2023'

doi: 10.1016/j.omto.2023.05.002
journal_title: Molecular Therapy Oncolytics
journal_nlm_ta: Mol Ther Oncolytics
publisher_name: American Society of Gene & Cell Therapy

keywords:
- oncolytic virus
- vaccinia virus
- LIVP
- interleukin-15
- interleukin-15 receptor alpha
- IL-15/IL-15Rα complex
- breast adenocarcinoma
- colon carcinoma

---
